OBJECTIVE:
There is an increasing prevalence of obesity worldwide that is pronounced among reproductive age women and we have previously shown adverse obstetrical outcomes with excessive weight gain, even if the maternal pre-pregnancy BMI is normal. Inflammatory markers such as C-peptide, interleukin 6 (IL-6), tumor necrosis factor alpha (TNF alpha), and monocyte chemotactic protein 1 (MCP-1) have also been shown to be elevated in obese compared to their normal weight cohorts. Furthermore metabolic markers ghrelin, insulin, leptin, amylin, gastric inhibitory polypeptide (GIP), Pancreatic polypeptide (PP), and Peptide YY (PYY) have also been shown to have derangements that produce a state of insulin resistance and glucose intolerance in obese compared to normal BMI subjects. The goal of their study was to robustly characterize the independent contribution of maternal BMI and gestational weight gain on maternal serum levels of inflammatory markers. STUDY DESIGN: Banked maternal serum samples from subjects with documented first trimester weight and BMI were utilized for analyte analyses. Validated, BMI-specific formulas were utilized to calculate gestational weight gain (GWG) which was categorized as either insufficient, sufficient or excess based on the Institute of Medicine Guidelines. Serum was analyzed for known inflammatory or oxidative pathway intermediates using the Luminex xMap system with the MILLIPLEX Human Metabolic Hormone Magnetic Bead Panel to measure C-Peptide, IL-6, TNF alpha, MCP-1 and metabolic markers ghrelin, insulin, leptin, amylin, GIP, PP, and PYY and the assays were read on Luminex 200. ANOVAs and Pearson's correlation coefficients were calculated for each marker. RESULTS: Of these markers, only leptin was found to be significantly different by GWG category (normal vs excessive, p-value ¼ 0.0154) and pre-pregnancy BMI (normal vs obese, p-value ¼ .00264). Leptin levels positively correlate with levels of c-peptide (r¼0.374; p<0.001), GIP (r¼0.222; p¼0.01466), glucagon (r¼0.283; p¼0.0017), and insulin (r¼0.271; p¼0.00278). CONCLUSION: Maternal leptin levels vary significantly with maternal gestational weight gain. Leptin was uniquely positively correlated with the maternal markers of inflammation: c-peptide, GIP, glucagon, and insulin. Taken together with our previous data showing adverse obstetrical outcomes we find that GWG is an important mediator of metabolic aberrations in pregnancy.
572 Can transfusion at delivery be prevented? Anemia during pregnancy and transfusion in an urban population Krunal Patel, Kristina Feldman, Matthew Romagano, Joseph Apuzzio, Shauna Williams, Lisa Gittens-Williams Rutgers New Jersey Medical School, Newark, NJ OBJECTIVE: Anemia is a risk factor for peripartum blood transfusion. Antenatal treatment of iron deficiency anemia may decrease the need for transfusion around the time of delivery. Our objective was to evaluate the effectiveness of treatment of moderate anemia (Hgb 7.0-9.9) in reducing risk of transfusion. STUDY DESIGN: A retrospective case control study of gravidas who delivered at a tertiary care urban hospital between 1/1/2012 to 12/31/ 2015 was performed. Patients who received blood transfusion during the admission for delivery comprised the study group. Nontransfused gravidas, matched to the study group for mode of delivery, served as controls, with a matching ratio of 1:4. Records were reviewed for antenatal treatment of anemia, hemorrhage risk factors and obstetric outcomes. Chi-square and Mann-Whitney tests were used. RESULTS: 6542 patients delivered during the study period, 177 (2.7%) patients received transfusion and 708 were selected as controls. Admission hemoglobin was significantly lower in the transfusion group compared to the control group (10 vs 11.6 g/dL, p<0.0001), with moderate anemia present at the time of admission in 46.3% of patients who underwent transfusion. Moderate anemia was diagnosed antenatally in 58 (32.8%) of the transfused patients and 73 (10.3%) of the controls (p<0.0001). Of those with antenatal moderate anemia, more of the patients in the control group had improvement in their hemoglobin at time of delivery (88% vs 54%, p¼0.006). 16 (27.6%) in the transfused group had no treatment; 9 were diagnosed after 35 weeks. Similarly in the control group, 18 (25%) were not treated; 7 were diagnosed after 35 weeks. CONCLUSION: There is a high rate of anemia in patients who require transfusion around the time of delivery. Rates of treatment of moderate anemia were similar, although more patients responded to treatment in the control group. Early diagnosis, aggressive correction of moderate anemia and compliance education and assessment during the antenatal period may decrease the rate of transfusion and associated maternal morbidities.
The link between weight changes during pregnancy and postpartum depression(PPD) has been analyzed in a few small studies, although the relationship remains unclear. We aimed to investigate the association between gestational weight gain(GWG) and PPD in women with class III obesity. 
